RemeGen
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (66)
A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
Started: 1/13/2026
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Started: 4/3/2026
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Started: 1/1/2026
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Started: 6/14/2022
Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
Started: 6/8/2023
A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders
Started: 1/29/2018
Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease
Started: 4/20/2026
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
Started: 4/28/2023
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
Started: 4/6/2023
Study of Telitacicept in Generalized Myasthenia Gravis
Started: 3/28/2023
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Started: 5/15/2025
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
Started: 3/29/2017
Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
Started: 10/16/2019
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Started: 11/28/2023
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Started: 6/30/2025
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Started: 2/10/2025
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Started: 4/29/2024
Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Started: 4/8/2024
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Started: 2/22/2024
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Started: 7/27/2023
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
Started: 1/11/2024
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Started: 11/27/2023
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
Started: 6/8/2023
RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial
Started: 5/13/2021
A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer
Started: 4/30/2026
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Started: 1/19/2024
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor
Started: 11/11/2022
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
Started: 8/4/2023
A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy
Started: 4/13/2020
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
Started: 12/20/2024
A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer
Started: 8/19/2019
Evaluation of RC28-E Injection in Diabetic Macular Edema
Started: 3/17/2021
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
Started: 11/4/2021
A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer
Started: 1/7/2019
A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
Started: 7/7/2020
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2
Started: 7/10/2018
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
Started: 11/21/2019
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
Started: 12/1/2015
A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer
Started: 12/28/2017
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
Started: 10/1/2015
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
Started: 8/11/2025
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
Started: 8/3/2023
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Started: 3/3/2022
A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
Started: 9/14/2023
A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy Subjects
Started: 8/5/2024
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Started: 6/14/2024
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
Started: 7/19/2023
RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC
Started: 9/7/2023
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
Started: 6/29/2023
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
Started: 4/30/2026
A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus
Started: 5/25/2023
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
Started: 3/13/2025
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
Started: 4/14/2020
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
Started: 3/10/2021
A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours
Started: 1/30/2023
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Started: 6/5/2023
A Study of RC48-ADC in Subjects With Advanced Breast Cancer
Started: 12/23/2016
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
Started: 9/26/2018
Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
Started: 5/11/2022
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
Started: 11/29/2021
Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration
Started: 4/15/2020
Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration
Started: 1/7/2019
A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors
Started: 3/1/2016
Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors
Started: 12/14/2015
A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects
Started: 9/17/2019